Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Inclusion Criteria: * Age ≥18 years * Must have a histologically- or cytologically, proven biliary tract cancer (BTC) previously treated with gemcitabine/cisplatin/anti-PD(L)1 therapy. * Must have evidence of radiological disease, must accept to have a tumor biopsy of an accessible lesion at baseline and on treatment. * Must have sufficient archival tumor tissue for next-generation sequencing (NGS) and immune-phenotyping. * Have a BTC containing at least one of the oncogenic mutation/alterations targeted by the vaccine. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Must have body weight of \>30 kg. * Patients must have adequate organ and marrow function defined by study-specified laboratory tests. * Patients with chronic or acute hepatitis B virus (HBV) or hepatitis C virus (HCV) infection must have disease controlled prior to enrollment. * Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test. * For both Women and Men, must use acceptable form of birth control while on study. * Must have a life expectancy of at least 12 weeks. * Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: * Participation in another clinical study with an investigational product during the last 2 weeks. * Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study. * Any of the following procedures or medications within 2 weeks prior to …